The stock of Amedisys Incorporated (NASDAQ:AMED) registered an increase of 13.22% in short interest. AMED’s total short interest was 1.34M shares in March as published by FINRA. Its up 13.22% from 1.18M shares, reported previously. With 320,300 shares average volume, it will take short sellers 4 days to cover their AMED’s short positions. The short interest to Amedisys Incorporated’s float is 4.06%. The stock is down 1.40% or $0.53 after the news, hitting $37.45 per share. About 67,310 shares traded hands. Amedisys Inc (NASDAQ:AMED) has declined 12.57% since July 27, 2015 and is downtrending. It has underperformed by 8.25% the S&P500.
Amedisys, Inc. is a health care at home company. The company has a market cap of $1.30 billion. Amedisys delivers home health and hospice care to more than 360,000 patients each year. It currently has negative earnings. The Firm has care network across 34 states.
The institutional sentiment increased to 1.31 in Q3 2015. Its up 0.25, from 1.06 in 2015Q2. The ratio improved, as 14 funds sold all Amedisys Inc shares owned while 57 reduced positions. 38 funds bought stakes while 55 increased positions. They now own 36.78 million shares or 26.39% more from 29.10 million shares in 2015Q2.
North Tide Capital Llc holds 13.24% of its portfolio in Amedisys Inc for 4.00 million shares. Kohlberg Kravis Roberts & Co. L.P. owns 4.84 million shares or 1.94% of their US portfolio. Moreover, Sivik Global Healthcare Llc has 1.47% invested in the company for 79,800 shares. The Georgia-based Caldwell & Orkin Inc has invested 0.58% in the stock. Bogle Investment Management L P De, a Massachusetts-based fund reported 191,662 shares.
Since March 16, 2015, the stock had 0 insider purchases, and 1 insider sale for $141,909 net activity. Ginn Scott G sold 3,063 shares worth $141,909. Washburn Donald A sold 20,000 shares worth $910,160. Ricchiuti Peter sold 900 shares worth $24,896. Jeter Jeffrey D sold 2,668 shares worth $75,478. The insider Netterville Jack L sold 10,000 shares worth $272,014.
Out of 7 analysts covering Amedisys Inc. (NASDAQ:AMED), 5 rate it “Buy”, 0 “Sell”, while 5 “Hold”. This means 50% are positive. Amedisys Inc. was the topic in 8 analyst reports since September 1, 2015 according to StockzIntelligence Inc. Oppenheimer upgraded the stock on February 8 to “Outperform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.